Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Disease 'Subsetting' Not Driving Jump In Orphan Designations, US FDA Says

Executive Summary

Preliminary study results suggest policy tweaks may not be necessary, even as an oncology orphan product rush appears to be coming.


Related Content

Orphan Designations For Pediatric Subgroups Of Common Diseases To End
Keytruda's New Tissue-Agnostic Indication Could Prompt Orphan Policy Changes
US FDA 'Medical Innovation Development Plan' Outlined By Gottlieb
Orphan Drug Act: Congressional, FDA, NORD Reviews Come Amid Pricing Debate
FDA's Pazdur To Retain Drug Approval Duties In Oncology Center Of Excellence
Orphan Drugs Should Be Rarer, Insurers Urge, Citing Price Increases
Orphan Designation Requests To Get Slower Reviews
Targeted Therapies On FDA’s Orphan Designation Radar





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts